HR+/HER2-negative Breast Cancer

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

SynDevRx
SynDevRxMA - Cambridge
1 program
1
EvexomostatPhase 1/2Small Molecule1 trial
Active Trials
NCT05455619RecruitingEst. Sep 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
SynDevRxEvexomostat

Clinical Trials (1)

NCT05455619SynDevRxEvexomostat

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Start: Aug 2022Est. completion: Sep 2026
Phase 1/2Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3m ago

Office Administrator

SystImmune
3m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
14m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
17m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
17m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)